Genesis to partner closely with detectives and investigators to convert tasks from weeks to minutes and turn mountains of artifacts into actionable insights

TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 16, 2026 /PRNewswire/ — Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today introduced early access to Cellebrite Genesis, a new purpose-built agentic AI product revolutionizing the way investigations get conducted.

“After a targeted terrorist attack, we gained early access to Genesis and immediately began pushing its boundaries. We identified evidence and generated leads of a quality and rate that we would otherwise have expected from dozens of dedicated, highly experienced analysts,” said a counter-terrorism detective from an Australian police agency with early access to Genesis. “We’ve used it to do things that surprised us, including generating critical new information from uploaded intelligence profiles, which changed the calculus and timeline entirely, achieving outcomes beyond what we believed possible.”

Cellebrite is the recognized leader in global investigative technology with nearly 3 million investigations annually and a track record of applying AI for more than a decade. Cellebrite Genesis offers customers instant delivery of transformational agentic AI with the precision, investigative rigor and public safety-grade guardrails directly into the hands of investigators, reinvigorating cold cases and strengthening narcotics, human trafficking and crimes against children investigations.

“Public safety agencies are being asked to do more with less. Budgets are under pressure, recruiting investigators is harder than ever and digital evidence volumes continue to grow. Genesis changes the game,” said Thomas E. Hogan, Cellebrite’s chief executive officer. “It delivers accurate, defensible AI that understands the nuances, context and relevance of different types of evidence. We’ve taken everything Cellebrite has learned in nearly two decades of digital forensics and combined it with the most advanced agentic AI to create an investigative partner that works at superhuman speed with forensic-grade precision. This is a transformational force for good.”

Cellebrite Genesis provides an intuitive, conversation-like experience to analyze mobile phone extractions, call detail records, documents, messages, images, video and more, turning them into immediate, actionable insights. Any analyst or investigator can master the platform in minutes. Genesis can be deployed on its own or alongside other Cellebrite solutions to dramatically accelerate investigations across a wide variety of complex data sources, crime types and scenarios.

“Genesis is powered by Cellebrite AI, which is a purpose-built intelligence layer developed from decades of trusted evidence analysis, courtroom-proven results and cumulative experiences,” said Ronnen Armon, chief products and technologies officer, Cellebrite. “As the creators of the most trusted digital evidence format in investigations, we know how to access, extract, decode and surface actionable, information that is defensible better than anyone. Genesis puts that capability directly in investigative teams’ hands empowering them with AI technologies that help them find the truth faster.”

Genesis delivers insights on demand, grounded in source evidence. Investigative data stays secure and private, aligned to the highest standards such as the National Institute of Standards and Technology (NIST) framework and Service Organization Control 2 (SOC 2) compliance. The customer remains in full control at every step

Cellebrite’s technology is used in nearly 3 million investigations worldwide each year, equipping more than 7,000 customers to resolve legally sanctioned investigations of child exploitation, homicide, terrorism, border control, sex crimes, Fentanyl and other organized crime, human trafficking, fraud, intellectual property theft, financial crimes, internal investigations, eDiscovery cases and more, while ensuring compliance with agency protocols and wide-ranging regulatory requirements.

Availability: Cellebrite Genesis is now open for early access.

Go to C2C, Cellebrite’s annual user conference to experience Cellebrite Genesis and Cellebrite Guardian Investigate firsthand. Learn more and register here.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

About Cellebrite

Cellebrite’s (Nasdaq: CLBT) mission is to protect communities, nations and businesses as a global leader in digital investigative and intelligence solutions. More than 7,000 global law enforcement agencies, defense and intelligence organizations and enterprises trust Cellebrite’s AI-powered software portfolio to make forensically sound digital data more accessible and actionable. Cellebrite technology allows customers to accelerate nearly 3 million legally sanctioned investigations annually, enhance sovereign security, elevate operational efficacy and efficiency and enable advanced mobile research and application security. Available via cloud, on-premises and hybrid deployments, Cellebrite’s technology enables its customers around the globe to advance their missions, elevate public safety and safeguard data privacy. To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com/investors and find us on social media @Cellebrite.

Contacts:

Media
Victor Cooper
Sr. Director of Corporate Communications and Content Strategy
victor.cooper@cellebrite.com
+1 404.804.5910

Investor Relations
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760

Local Las Vegas Robotics Company to Conduct Testing That May Lead to Broader Deployments

SINGAPORE, March 16, 2026 /PRNewswire/ — YY Group Holding Limited (NASDAQ: YYGH) today announced the launch of a robotics pilot program in Las Vegas, Nevada, where the Company will begin testing hospitality and security robots in collaboration with a local Las Vegas robotics company. The pilot program is expected to run for approximately one year, with the goal of evaluating how robotics solutions can improve operational efficiency, service delivery, and security across hospitality environments.

Las Vegas, one of the largest hospitality markets in the world, provides an ideal environment for testing robotics technology at scale. The program will focus on deploying robotics solutions designed to assist with hospitality services and security operations across hotels and commercial properties.

The testing program will evaluate robotics capabilities in real-world hospitality settings, including hotel operations, guest service support, and commercial security monitoring. YY Group believes robotics may help hospitality operators address labor challenges while improving consistency and efficiency in service and safety operations.

If the pilot program proves successful, the Company believes the initiative may lead to additional robotics deployments and potential orders across hospitality properties and security operations throughout Las Vegas.

“Robotics is rapidly becoming an important part of our business,” said Mike Fu, Chairman, Chief Executive Officer and Founder of YY Group Holding Limited. “We have already begun deploying robotics solutions in Malaysia and Singapore, including some of the finest hotels in the world. Given Las Vegas’ position as the entertainment capital of the world, it is a natural next step for us to test our robotics products in this dynamic market. We believe the city provides an ideal environment to demonstrate how robotics can support hospitality operations and enhance security services at scale.”

Las Vegas attracts tens of millions of visitors annually, making it one of the most active hospitality hubs globally. The Company believes robotics may play an increasingly important role in helping hotels and commercial properties support staff, improve operational efficiency, and enhance security coverage.

YY Group expects to provide updates as testing progresses and as additional opportunities for robotics deployment are evaluated.

About YY Group Holding Limited

YY Group Holding Limited (Nasdaq: YYGH) is a Singapore-headquartered, technology-enabled platform providing flexible, scalable workforce solutions and integrated facility management (IFM) services across Asia and beyond. The Group operates through two core verticals: on-demand staffing and IFM, delivering agile, reliable support to industries such as hospitality, logistics, retail, and healthcare.

Leveraging proprietary digital platforms and IoT-driven systems, YY Group enables clients to meet fluctuating labor demands and maintain high-performance environments. In addition to its core operations in Singapore and Malaysia, the Group maintains a growing presence in Asia, Europe, Africa, Oceania and the Middle East.

Listed on the Nasdaq Capital Market, YY Group is committed to service excellence, operational innovation, and long-term value creation for clients and shareholders.

For more information on the Company, please visit https://yygroupholding.com/.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the YY Group Holding Limited’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to, (i) growth of the hospitality market (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, and (vi) our future business development, results of operations and financial condition. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release, and YY Group Holding Limited undertakes no duty to update such information, except as required under applicable law.

Investor Contact
Jason Phua Zhi Yong, Chief Financial Officer
YY Group
enquiries@yygroupholding.com

Local Las Vegas Robotics Company to Conduct Testing That May Lead to Broader Deployments

SINGAPORE, March 16, 2026 /PRNewswire/ — YY Group Holding Limited (NASDAQ: YYGH) today announced the launch of a robotics pilot program in Las Vegas, Nevada, where the Company will begin testing hospitality and security robots in collaboration with a local Las Vegas robotics company. The pilot program is expected to run for approximately one year, with the goal of evaluating how robotics solutions can improve operational efficiency, service delivery, and security across hospitality environments.

Las Vegas, one of the largest hospitality markets in the world, provides an ideal environment for testing robotics technology at scale. The program will focus on deploying robotics solutions designed to assist with hospitality services and security operations across hotels and commercial properties.

The testing program will evaluate robotics capabilities in real-world hospitality settings, including hotel operations, guest service support, and commercial security monitoring. YY Group believes robotics may help hospitality operators address labor challenges while improving consistency and efficiency in service and safety operations.

If the pilot program proves successful, the Company believes the initiative may lead to additional robotics deployments and potential orders across hospitality properties and security operations throughout Las Vegas.

“Robotics is rapidly becoming an important part of our business,” said Mike Fu, Chairman, Chief Executive Officer and Founder of YY Group Holding Limited. “We have already begun deploying robotics solutions in Malaysia and Singapore, including some of the finest hotels in the world. Given Las Vegas’ position as the entertainment capital of the world, it is a natural next step for us to test our robotics products in this dynamic market. We believe the city provides an ideal environment to demonstrate how robotics can support hospitality operations and enhance security services at scale.”

Las Vegas attracts tens of millions of visitors annually, making it one of the most active hospitality hubs globally. The Company believes robotics may play an increasingly important role in helping hotels and commercial properties support staff, improve operational efficiency, and enhance security coverage.

YY Group expects to provide updates as testing progresses and as additional opportunities for robotics deployment are evaluated.

About YY Group Holding Limited

YY Group Holding Limited (Nasdaq: YYGH) is a Singapore-headquartered, technology-enabled platform providing flexible, scalable workforce solutions and integrated facility management (IFM) services across Asia and beyond. The Group operates through two core verticals: on-demand staffing and IFM, delivering agile, reliable support to industries such as hospitality, logistics, retail, and healthcare.

Leveraging proprietary digital platforms and IoT-driven systems, YY Group enables clients to meet fluctuating labor demands and maintain high-performance environments. In addition to its core operations in Singapore and Malaysia, the Group maintains a growing presence in Asia, Europe, Africa, Oceania and the Middle East.

Listed on the Nasdaq Capital Market, YY Group is committed to service excellence, operational innovation, and long-term value creation for clients and shareholders.

For more information on the Company, please visit https://yygroupholding.com/.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the YY Group Holding Limited’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to, (i) growth of the hospitality market (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, and (vi) our future business development, results of operations and financial condition. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release, and YY Group Holding Limited undertakes no duty to update such information, except as required under applicable law.

Investor Contact
Jason Phua Zhi Yong, Chief Financial Officer
YY Group
enquiries@yygroupholding.com

ORLANDO, Fla., March 16, 2026 /PRNewswire/ — As automatic litter boxes gain traction in the U.S., driven by the rapid growth of the smart pet care market, compatibility challenges around litter performance have emerged as a growing concern.

According to market research from Persistence Market Research and Credence Research, the global smart and automatic cat litter box market is expanding rapidly, with the smart litter box segment projected to grow from approximately USD 1.0 billion in 2024 to over USD 2.1 billion by 2032. This growth reflects rising adoption of self-cleaning systems designed to reduce daily maintenance for pet owners.

However, as more households rely on automated litter boxes, users frequently report maintenance-related issues—such as residue buildup, cleaning inefficiencies, and mechanical interruptions—often linked to the litter used.

Lady N, a Taiwan-born, design- and engineering-driven cat litter brand, is entering the North American market to address this gap by developing tofu cat litter engineered specifically for automatic litter box systems.

Lady N will exhibit at Global Pet Expo 2026 in Orlando, Florida, at Booth 3484, where the team will present its machine-compatible tofu cat litter solutions and meet with retailers, distributors, and OEM partners.

In automated litter box environments, litter performance depends not only on material type but also on how the formulation responds to repeated mechanical cycling. Some conventional formulations—originally designed for manual use—may exhibit dust generation, residue carryover, or liner adhesion under automated conditions.

Consumer feedback across online communities and e-commerce platforms frequently highlights sifting inefficiencies and performance inconsistency tied to particle geometry and flow behavior during cleaning cycles.

To address these system-level bottlenecks, Lady N engineered its tofu litter with a focus on precision particle engineering, optimized flow dynamics, enhanced residue control, and consistent machine cycle performance—supporting reliable operation across major automatic litter box designs.

Since entering North America in 2023, Lady N has demonstrated strong momentum:

• USD 70,000 in 2023
• USD 470,000 in 2024
• USD 1.45 million in 2025
• Projected USD 4 million in 2026

This growth reflects increasing demand for litter solutions that combine sustainability with true machine compatibility.

To support long-term growth and reduce carbon emissions, Lady N is building a localized U.S. supply chain. A West Coast warehouse in Northern California is already in operation, with an East Coast facility planned to improve nationwide distribution efficiency.

Lady N has selected Dallas, Texas, as the site for its future manufacturing facility and is actively recruiting key leadership roles, including a Plant Manager and HR Manager, to support local job creation.

“Automatic litter boxes are common in U.S. homes, but truly compatible litters are not. Lady N was created to fill this overlooked gap through engineering-driven and sustainable solutions.” said Naimei Hsu, Brand Manager at Lady N.

Retailers, distributors, and OEM partners are invited to meet the Lady N team at Booth 3484 during Global Pet Expo 2026 to explore partnership opportunities.

About Lady N

Founded in 2021 and part of ShepherdTech Group, Lady N is a Taiwan-born, design-driven cat litter brand built on plant-based materials and science-backed odor control. Guided by “Made for cats, loved by humans, and kind to the planet,” Lady N creates cleaner, safer, and more delightful home experiences.

Since entering North America in 2023, Lady N has grown rapidly and earned recognition from Amazon Global Selling as a fast-rising brand, becoming a trusted next-generation litter choice for cat families. ladynpet.com/us

Demonstrating integrated Satcom innovations across land, sea, and air with rugged computing, AI-enabled systems, and resilient communications

WASHINGTON, March 16, 2026 /PRNewswire/ — Ubiqconn Technology, a leading provider of industrial Internet of Vehicles (IoV) and embedded Internet of Things (IoT) solutions, will showcase its latest satellite-enabled connectivity technologies at SATShow Week 2026, taking place March 23–26 in Washington, D.C. Visitors can explore Ubiqconn Technology’s innovations at Booth #2747.

Under the theme “Ubiquitous Connectivity: Integrating Satcom Across Land, Sea, and Air,” Ubiqconn Technology will demonstrate mission-critical solutions that combine rugged computing, AI-powered systems, and Iridium satellite communications to enable resilient connectivity in remote and demanding environments.

For maritime environments, Ubiqconn Technology will also present the Marlin GMDSS system and SGA110 Mobile Gateway, combining weather intelligence, vessel tracking, and dependable VoIP and satellite communications to enhance situational awareness and ensure reliable communications for offshore, ocean-going, and emergency marine operations.

RuggON Corp., a subsidiary of Ubiqconn Technology and a leading provider of rugged mobile computing solutions, will present a range of mission-critical platforms at the show.

A key highlight is the SPARK 7 Ground Control System (GCS), an advanced controller for unmanned platforms integrating AI-driven autonomous navigation and real-time image analysis. Designed for aerial and unmanned operations, the system enables precise command, control, and mission coordination across a wide range of defense, government, and remote operational scenarios.

Supporting land-based deployments, RuggON will also showcase its rugged computing platforms, including the SOL 7 rugged tablet and VORTEX 07X vehicle-mounted computer, both equipped with Iridium satellite capabilities to deliver dependable data transmission and operational visibility in harsh terrestrial environments.

“Reliable satcom infrastructure is increasingly essential for organizations operating in remote and mission-critical environments,” said Paul Hsieh, CEO of Ubiqconn Technology. “Our focus is on delivering ruggedized, reliable, and resilient platforms that support continuous communications and operational readiness across land, sea, and air.”

About Ubiqconn Technology

Ubiqconn Technology is a leading provider of rugged mobile and satellite connectivity solutions, delivering value-added services across critical sectors including satellite communication, maritime, rugged smart mobility, and government. Guided by the vision of “Ubiquitous Connectivity,” Ubiqconn Technology emphasizes user-centric thinking, agile go-to-market strategies, and engineering excellence to help clients solve real-world challenges and bring innovation to life. Its subsidiary, RuggON Corp., designs and manufactures rugged mobile computing devices for industrial and mission-critical environments.

For more information, please visit our website: www.ubiqconn.com and www.ruggon.com.

• AVTOZMA^® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available in the United States
• The launch of AVTOZMA SC further diversifies Celltrion’s immunology portfolio beyond TNF-alpha and IL-12/23 inhibitors providing a broader range of treatment solutions for immune-mediated inflammatory diseases

INCHEON, South Korea, March 16, 2026 /PRNewswire/ — Celltrion, Inc. today announced that AVTOZMA^® (tocilizumab-anoh) subcutaneous (SC) formulation is now commercially available to patients in the United States.

With this launch, Celltrion’s AVTOZMA becomes one of the first tocilizumab biosimilars to have both an intravenous (IV) and a SC formulation approved by the U.S. Food and Drug Administration (FDA) and available on the U.S. market.

“The introduction of AVTOZMA SC is a pivotal moment for Celltrion, underscoring our dedication to delivering effective, accessible and user-friendly therapies for patients with chronic inflammatory diseases,” said Thomas Nusbickel, Chief Commercial Officer of Celltrion USA. “By offering both IV and SC formulations, we aim to provide patients and healthcare professionals with greater flexibility in treatment decisions, while continuing to broaden our immunology portfolio with therapies that address diverse inflammatory pathways.”

The SC formulation of AVTOZMA is indicated for the treatment of rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA). AVTOZMA SC is available in a 162 mg/0.9 mL solution for injection in a single-dose prefilled syringe or a single-dose prefilled autoinjector, allowing patients the flexibility and convenience of administering their treatment at home. ^[1]

Celltrion provides support to U.S. patients prescribed AVTOZMA through its patient support program, Celltrion CONNECT™. Celltrion CONNECT™ offers tailored support to its patients and caregivers with a full range of services including injection training, reimbursement assistance and educational resources to patients and healthcare professionals.

Notes to Editors:

About AVTOZMA^® (CT-P47, tocilizumab-anoh)
AVTOZMA^® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab, AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. In July 2025, the FDA approved an additional indication for the intravenous (IV) formulation of AVTOZMA for the treatment of cytokine release syndrome (CRS) in adult and pediatric patients aged two years and older.

INDICATION 

AVTOZMA^® (tocilizumab-anoh) IV is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

• Rheumatoid Arthritis (RA): Adult patients with moderately to severely active RA who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
• Giant Cell Arteritis (GCA): Adult patients with GCA.
• Polyarticular Juvenile Idiopathic Arthritis (pJIA): Patients 2+ years-old with active pJIA.
• Systemic Juvenile Idiopathic Arthritis (sJIA): Patients 2+ years-old with active sJIA.
• Cytokine Release Syndrome (CRS): Adults and pediatric patients 2+ years-old with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome
• COVID-19: Hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

AVTOZMA^® (tocilizumab-anoh) SC is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

• Rheumatoid Arthritis (RA): Adult patients with moderately to severely active RA who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
• Giant Cell Arteritis (GCA): Adult patients with GCA.
• Polyarticular Juvenile Idiopathic Arthritis (pJIA): Patients 2+ years-old with active pJIA.
• Systemic Juvenile Idiopathic Arthritis (sJIA): Patients 2+ years-old with active sJIA.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS INFECTIONS

AVTOZMA^® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants.

If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include:

• Active tuberculosis (TB) which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during treatment (except in COVID-19 patients) and treat latent infections before starting AVTOZMA.
• Invasive fungal infections: Such as candidiasis, aspergillosis, and pneumocystis, may present as disseminated rather than localized disease.
• Opportunistic infections, including bacterial, viral and other opportunistic pathogens.

Monitor patients for signs of infection, including TB, during and after AVTOZMA treatment.
Contraindications: Known hypersensitivity to tocilizumab products.
Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled.

Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management.

Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop.

Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts.

Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant.

Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity.

Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders.

Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended.

Live Vaccines. Avoid concurrent use with AVTOZMA.

Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions.

For more information, see Full Prescribing Information.

About Celltrion

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media – LinkedIn, Instagram, X, and Facebook.

About Celltrion USA

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion’s FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA^® (infliximab-dyyb), TRUXIMA^® (rituximab-abbs), HERZUMA^® (trastuzumab-pkrb), VEGZELMA^® (bevacizumab-adcd), YUFLYMA^®(adalimumab-aaty), AVTOZMA^® (tocilizumab-anho), STEQEYMA^® (Ustekinumab-stba) STOBOCLO^® (denosumab-bmwo), OSENVELT^® (denosumab-bmwo), and OMLYCLO^® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com and stay updated with our latest news and events on our social media – LinkedIn.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, “anticipates”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

AVTOZMA^® is a registered trademark of Celltrion Inc.
ACTEMRA^® is a registered trademark of Chugai Pharmaceutical Co., Ltd. 

References

For further information please contact: 
Brendi Bluitt
bbluitt@jpa.com  
+1 202-545-7722

• Economy seat pitch on aircraft HL8701 increased from 31 to 33 inches
• Total seat count adjusted from 344 to 326 as part of cabin space and comfort upgrades, including new carpet installation

SEOUL, South Korea, March 16, 2026 /PRNewswire/ — Air Premia, Korea’s only hybrid airline, has enhanced passenger comfort by reducing the total number of seats while expanding seat pitch to enhance passenger comfort.

The airline announced that the economy class seat pitch on aircraft HL8701 has been increased from 31 inches to 33 inches. Following the adjustment, the aircraft’s total seat capacity has been reduced from 344 seats to 326 seats, a decrease of 18 seats.

Unlike the common industry practice of increasing seat density to improve profitability, Air Premia has focused on expanding seat space to improve passenger comfort and overall travel experience.

The aircraft completed its seat reconfiguration in mid-March and entered service on March 16. Passengers on flights operated by this aircraft will now experience the expanded seat pitch.

Air Premia has been continuously improving seat space to enhance comfort for passengers traveling on long-haul routes. In 2024, the airline also reconfigured two aircraft previously operating with 338 seats, reducing them to 320 seats while expanding economy class seat pitch.

The airline is currently carrying out sequential seat adjustments on aircraft configured with 344 seats, with plans to expand the economy class seat pitch on all aircraft to 33 inches or more within this year.

Air Premia currently operates a fleet of nine aircraft, configured with 309 seats (three aircraft), 320 seats (two aircraft), 326 seats (two aircraft), and 344 seats (two aircraft). All aircraft except the 344-seat configuration currently operate with an economy class seat pitch of 33 inches or greater.

Along with the seat pitch expansion, Air Premia has also replaced the cabin carpet. The newly installed carpet is produced using digital printing technology, allowing the airline’s brand identity to be naturally incorporated into the cabin interior design.

In addition, the new carpet is lighter than the previous version, contributing to aircraft weight reduction and supporting environmental benefits such as improved fuel efficiency.

“Air Premia is committed to continuously improving seat space and the cabin environment so that passengers traveling on long-haul routes can enjoy a more comfortable journey,” an Air Premia official said. “We will continue to introduce various service enhancements to further elevate the customer experience.”